Shares of Revance Therapeutics Inc (NASDAQ:RVNC) have earned an average rating of “Buy” from the fourteen ratings firms that are covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, three have issued a hold recommendation and ten have assigned a buy recommendation to the company. The average twelve-month price objective among analysts that have updated their coverage on the stock in the last year is $47.78.
RVNC has been the topic of a number of analyst reports. Cantor Fitzgerald set a $50.00 price objective on shares of Revance Therapeutics and gave the company a “buy” rating in a research note on Wednesday, November 29th. Mizuho reiterated a “buy” rating and set a $54.00 price objective on shares of Revance Therapeutics in a research note on Friday, January 5th. Cowen set a $55.00 price objective on shares of Revance Therapeutics and gave the company a “buy” rating in a research note on Wednesday, January 17th. BidaskClub lowered shares of Revance Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Wednesday, February 7th. Finally, Barclays set a $40.00 price objective on shares of Revance Therapeutics and gave the company a “buy” rating in a research note on Tuesday, December 19th.
Revance Therapeutics (NASDAQ:RVNC) traded up $0.70 on Friday, hitting $31.45. 337,039 shares of the stock were exchanged, compared to its average volume of 342,552. The stock has a market capitalization of $1,170.24, a price-to-earnings ratio of -7.88 and a beta of 1.36. Revance Therapeutics has a 12 month low of $18.00 and a 12 month high of $37.45.
Large investors have recently modified their holdings of the stock. SG Americas Securities LLC bought a new stake in shares of Revance Therapeutics in the third quarter worth $144,000. Cowen Inc. bought a new stake in shares of Revance Therapeutics in the fourth quarter worth $225,000. Teacher Retirement System of Texas bought a new stake in shares of Revance Therapeutics in the fourth quarter worth $255,000. Quinn Opportunity Partners LLC bought a new stake in shares of Revance Therapeutics in the fourth quarter worth $325,000. Finally, Two Sigma Advisers LP bought a new stake in shares of Revance Therapeutics in the fourth quarter worth $343,000. Institutional investors and hedge funds own 97.56% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “Revance Therapeutics Inc (RVNC) Receives Average Rating of “Buy” from Brokerages” was first published by StockNewsTimes and is owned by of StockNewsTimes. If you are reading this piece on another domain, it was illegally copied and republished in violation of international trademark and copyright legislation. The legal version of this piece can be viewed at https://stocknewstimes.com/2018/03/14/revance-therapeutics-inc-rvnc-receives-average-rating-of-buy-from-brokerages.html.
Revance Therapeutics Company Profile
Revance Therapeutics, Inc is a clinical-stage biotechnology company. The Company is focused on the development, manufacturing and commercialization of botulinum toxin products for multiple aesthetic and therapeutic indications. Its peptide technology enables delivery of botulinum toxin type A through two investigational drug product candidates, DaxibotulinumtoxinA for Injection (RT002), or RT002 injectable, and DaxibotulinumtoxinA Topical Gel (RT001), or RT001 topical.
Receive News & Ratings for Revance Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revance Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.